Daratumumab and hyaluronidase-fihj plus pomalidomide and dexamethasone have been approved by the FDA for the treatment of multiple myeloma

Share This Post

August 2021: Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) have been approved by the Food and Drug Administration in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy that included lenalidomide and a proteasome inhibitor.

In APOLLO (NCT03180736), 304 patients were randomised (1:1) to Darzalex Faspro with pomalidomide and dexamethasone (Pd) against Pd alone in an open-label, active-controlled trial. Patients were given Darzalex Faspro 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) subcutaneously once weekly from Weeks 1 to 8, once every 2 weeks from Weeks 9 to 24, and once every 4 weeks starting with Week 25 until disease progression or unacceptable toxicity, along with pomalidomide 4 mg once daily orally on days 1-21 of each 28-day cycle; and dexamethasone 40 mg once daily or

The primary effectiveness metric was progression-free survival (PFS). The median PFS in the Darzalex Faspro-Pd therapy group was 12.4 months compared to 6.9 months in the Pd treatment group (HR 0.63; 95 percent CI: 0.47, 0.85; p=0.0018), indicating a 37 percent lower risk of disease progression or mortality in patients treated with Darzalex Faspro-Pd versus Pd.

Fatigue, pneumonia, upper respiratory tract infection, and diarrhoea are the most prevalent adverse events in individuals with multiple myeloma who received Darzalex Faspro-Pd (20%).

Darzalex Faspro’s recommended dosage is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) injected subcutaneously into the abdomen over 3 to 5 minutes according to the manufacturer’s instructions.

Reference: https://www.fda.gov/

Check details here.

 

Take second opinion on multiple myeloma treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Limkato Korea’s first CAR T Cell therapy
CAR T-Cell therapy

Limkato: Korea’s first CAR T Cell therapy

South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy by **Curocell** in 2023. This milestone reduces reliance on foreign treatments and boosts Korea’s position in the global biotech industry. With strong government support and cutting-edge research, Korea is poised to advance CAR T therapies further, expanding applications and improving accessibility for cancer patients.

TIL therapy for melanoma in China
Melanoma

TIL therapy for melanoma in China

Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments have failed. In China, the adoption of TIL therapy is gaining momentum, offering new hope to patients battling this aggressive form of skin cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟